Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145234 · ClinicalTrials.gov registry record · Phase 1
Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects
A Phase 1 study of Healthy Adults, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT02145234: Completed Phase 1 study of Healthy Adults, sponsored by Hoffmann-La Roche.
NCT02145234 is a Phase 1 study of Healthy Adults that has completed, run by Hoffmann-La Roche. The registered enrollment target is 140 participants, above the 82-participant average among 33 other Healthy Adults trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02145234, a Phase 1 study of Healthy Adults, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-986089 in healthy adult subjects.
Conditions Studied
Interventions
- DRUG BMS-986089
- DRUG Placebo matching with BMS-986089
Study Locations (1)
California
- Wcct Global, Llc - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-06-30 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 1 |
What the finished NCT02145234 record still lists
NCT02145234 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 33 other Healthy Adults trials with a reported enrollment target (71% higher).
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which BMS-986089 is the first listed.
NCT02145234 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02145234 about?
NCT02145234 is a clinical study titled "Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects". The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-986089 in healthy adult subjects.
What is the current status of trial NCT02145234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2014-06-30. Estimated completion is 2016-02-29.
What conditions does trial NCT02145234 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT02145234?
The interventions under investigation include: BMS-986089 (DRUG), Placebo matching with BMS-986089 (DRUG).
Who is sponsoring clinical trial NCT02145234?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02145234 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02145234's enrollment target sits among peer trials
140 3rd of 33 higher than 31 of 33 other Healthy Adults trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI